News | June 22, 2022
MedC Biopharma partners with A2W Pharma to develop cannabinoid therapeutics
Bringing next-gen cannabinoid therapeutics to cancer patients
Bringing next-gen cannabinoid therapeutics to cancer patients
The ground floor of the formulation development laboratory is focused on solid orals, the first floor on injections, and the second floor houses the analytical lab
The abstract is about the cohort A, stage I of the ongoing global phase ? trial that evaluating the safety and efficacy of Catumaxomab in advanced GC patients with peritoneal metastasis
Glofitamab has the potential to offer a readily available, fixed-duration CD20xCD3 bispecific antibody treatment approach for people with aggressive lymphoma
The AI and technology upgrades allow doctors to choose their medical speciality and even spelling preferences to set their own speech model
The new facility at Dombivli is the fifth ASG Eye Hospital in Maharashtra
Phase I trial in Rwanda and South Africa aims to evaluate mRNA HIV vaccine antigen for safety and immunogenicity and strengthen regional scientific capacity
In addition, common light chain antibodies generated by RenLite mice can greatly improve the efficiency of downstream assembly of complex drug molecules such as bispecific antibodies and bispecific antibody-drug conjugates (bsADCs)
To meet the growing global demand for respiratory active pharmaceutical ingredients (APIs), Inke is to invest €9 million into its production plant to reinforce focus on inhalation micronised APIs
This partnership allows both companies to become first movers to bridge an inevitable gap with the largest organizations in the pharmaceutical, nutraceutical, cosmetic, and veterinary sectors
Subscribe To Our Newsletter & Stay Updated
